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Background: The introduction of direct-acting antiviral agents (DAAs) for the treatment of chronic hepatitis C virus
(HCV) infection in patients undergoing hemodialysis (HD) has improved sustained virological response (SVR) rates.
Our aim was to assess the characteristics of the virological response to daclatasvir (DCV) and asunaprevir (ASV)
combination therapy for HCV in HD patients.
Methods: A multicenter prospective study was conducted at eight centers in Japan. Patients on HD with chronic
genotype 1b HCV infections were orally administered DCV and ASV for 24 weeks at doses of a 60-mg capsule once
daily and a 100-mg tablet twice daily, respectively. The primary endpoint of this trial was the proportion of patients
with a sustained virological response at 24 weeks after the treatment ended (SVR24). We also investigated the
characteristics associated with the virological response to combination therapy.
Results: Thirty patients were enrolled in this study, and the proportion that achieved an SVR24 after treatment was
83.3% (25/30). Virological failure was observed in 4 patients (13.3%). Two exhibited virological breakthrough at weeks
16 and 20 of drug administration, and viral relapse occurred in 2 patients at weeks 4 and 8 after the end of treatment.
Virological failure was defined as HCV-RNA levels exceeding 5.5 log10 IU/mL, and resistance-associated variants (RAVs)
NS5A-L31M/V and Y93H were not exhibited at baseline.
Conclusions: DCV and ASV therapy for chronic HCV on HD was significantly effective. Most importantly, patients with
the low viral loads undergoing HD demonstrated a higher response to combination therapy regardless of RAV.
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Hepatitis C virus (HCV) has been recognized as the
most important causative agent of liver disease in
patients receiving long-term hemodialysis (HD) in both
developed and less-developed countries [1]. There are
six distinguishable HCV genotypes, and the use of con-
ventional interferon (IFN), pegylated IFN-α, or a com-
bination of IFN with ribavirin for treatment depends on
the genotype of the HCV virus [2]. Although treatment
options for patients on HD are the same as for the
general population, it is important to consider that
treatment-related toxicity with IFN and ribavirin occurs
frequently in patients on HD [3, 4]. According to the
KDIGO (Kidney Disease Improving Global Outcome)
guidelines, monotherapy with standard IFN is the ther-
apy of choice for HCV-infected patients on maintenance
HD [5]. Although IFN-related therapy achieves a sustained
virological response (SVR) in 33–45% of HD patients with
genotype 1, alternative therapies are required [4].
Presently, direct-acting antiviral agents (DAAs) have
assumed a more prominent role in the treatment of
patients with HCV [6–10]. The introduction of DAAs
has improved SVR rates and shortened treatment du-
rations. DAAs also enabled successful treatment with-
out IFN therapy [7]. In Japan, a phase III study
demonstrated that a 24-week combined regimen of
daclatasvir (DCV) and asunaprevir (ASV) was highly
effective in patients with HCV genotype 1b infections
[10]. DCV was the first nonstructural protein 5A
(NS5A) replication complex inhibitor to show poten-
tial efficacy against all HCV genotypes [11–14]. ASV
is a second-generation NS3 (nonstructural protein 3)
protease inhibitor that exhibited strong antiviral activ-
ity against HCV genotypes 1 and 4. It has been
shown to act by inhibiting the viral nonstructural 3/
4A serine protease required for viral replication [15, 16].
The pharmacokinetics of DCV and ASV, which are
eliminated primarily by hepatic metabolism, have
been assessed in patients with end-stage renal dis-
ease, which indicated that dose adjustments of either
drug were unnecessary in cases of severe renal dys-
function. Recently, two prospective studies reported
the efficacy of DCV and ASV combination therapy
for the treatment of chronic HCV in patients under-
going HD, showing dramatically improved rates of
sustained virological response at 12 weeks after
treatment (SVR12) compared with monotherapy with
standard IFN [17, 18]. However, it remains unclear
whether end-stage renal disease, including those in
patients on HD, affects the viral response to DAA-
based antiviral therapy for HCV. Therefore, we stud-
ied the characteristics associated with the virological
response to DCV and ASV combination therapy for
HCV on HD patients.Methods
Study design and patients
A multicenter prospective study was conducted at eight
centers in Japan. The enrollment commenced in February
2015, and the study was completed in August 2016.
Patients with chronic genotype 1b HCV infection under-
going HD received DCV and ASV for 24 weeks. DCV and
ASV were administered orally at doses of a 60-mg capsule
once daily and a 100-mg tablet twice daily, respectively,
according to the manufacturer’s prescribing information
for both medications. The discontinuance criteria for the
enrolled patients included (1) viral breakthrough occur-
rence (increase in plasma HCV-RNA levels exceeding 1
log10 IU/mL compared with the lowest recorded on-
treatment value), (2) a lower than 2 log10 IU/mL decrease
in HCV-RNA levels compared with those at the base-
line and at week 8, (3) occurrence of severe adverse
events (≥grade 3) according the National Cancer
Institute Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0, and (4) the patient’s
desire to terminate.
Eligibility criteria
This study enrolled patients with chronic HCV genotype
1b infection for at least 6 months and plasma HCV-
RNA levels exceeding 2 log10 IU/mL. Eligible patients
consisted of men and women who were treatment-naïve
or treatment-experienced (previously treated with an
IFN-based therapy), over 20 years of age, and currently
undergoing HD.
The main exclusion criteria included the presence of
(1) decompensated liver cirrhosis (Child-pugh B and C),
(2) hepatocellular carcinoma, (3) infection/co-infection
with hepatitis B virus (HBV) or human immunodefi-
ciency virus (HIV), (4) previous exposure to IFN-based
therapy within 1 month before drug administration, (5)
previous exposure to DAA inhibitors, and (6) defined
laboratory abnormalities during screening. Furthermore,
patients with alanine aminotransferase (ALT) levels
greater than five times the upper limit of the normal
range, platelet, and white blood cell (WBC) counts lower
than 50,000 and 4000/mm3, respectively, and hemoglobin
levels less than 8.5 g/dL, were also excluded.
Clinical parameters
The clinical characteristics evaluated were the demo-
graphic information, plasma HCV-RNA levels, and base-
line laboratory data before and after the study drug
administration. Blood samples were collected at each
study visit before a dialysis, and the plasma HCV-RNA
levels were quantified using the Cobas TaqMan version
2.0 assay (Roche Diagnostics, Tokyo, Japan); the lower
limits of quantification were 1.2 log10 IU/mL. The HCV-
RNA levels were measured at baseline and at weeks 0, 2,
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4, 8, 12, and 24. The resistance-associated variants
(RAVs) of NS5A-Y93H and L31M/V were identified
using direct sequencing [19], which was conducted on
all enrolled patients. The laboratory tests performed
were the analysis of hemoglobin, WBC count, neutro-
phils, platelets, serum albumin, blood urea nitrogen
(BUN), creatinine, total bilirubin, aspartate aminotrans-
ferase (AST), ALT, and α-fetoprotein levels.
Efficacy
The primary endpoint of this trial was the proportion of
patients with a sustained virological response 24 weeks
after the treatment ended (SVR24) as determined by
using intention-to-treat analysis. The secondary end-
points were the proportion of patients with undetectable
HCV-RNA levels at weeks 4, 8, 12, 16, 20, and 24, at the
end of the treatment, and at weeks 4, 8, and 12 after the
treatment ended. We also investigated the characteristics
associated with the virological response to the combin-
ation therapy. To study the pharmacological effects of
combination therapy, laboratory data on blood biomarkers
were assessed.
Safety assessment
To evaluate drug safety during the trial period, we
assessed the adverse events that occurred after the com-
mencement of trial drug administration at each study
visit. The data on all adverse events were collected from
the start of study drug administration to up to 30 days
after the last study drug dosing. The severity of anyFig. 1 Study flow diagramserious or nonserious adverse events was graded using
CTCAE, version 4.0.
Statistical evaluation
Our estimation of the SVR24 rates in patients undergo-
ing HD was 85% based on previous studies [10]. With
an alpha of 0.05 and power of 80%, 30 patients were
required for this trial. Under the principles of intent to
treat, the population analyzed consisted of all patients
who signed informed consent forms. The data were
analyzed using the statistical software JMP 11.0.1
(Statistical Analysis Software, SAS Institute). All the
data were expressed as mean ± standard deviation, and
the Wilcoxon signed-rank test was used for the ana-
lysis of the paired data. All differences with a P value
<0.05 were considered significant.
Results
Characteristics of patients
A total of 33 patients were assessed in February 2015,
and the study was completed in August 2016 (Fig. 1). Of
these 33 patients, 3 patients dropped out during the
run-in period due to failure to meet the criteria to com-
mence treatment. The remaining 30 patients received
the combination therapy, and of these, only 1 patient did
not complete the study due to nontreatment-related
death (sudden death at week 13 of drug administration).
The enrolled patients’ demographics and other baseline
clinical characteristics are summarized in Table 1. All
patients who were enrolled in the trial were included in
the analyses. The patients’ mean age was 65.5 ± 7.7 years
Table 1 Patient baseline clinical characteristics
Characteristics All patients
N 30
Age, years 65.5 ± 7.7
Sex, male n (%) 23 (76.7)
Duration of hemodialysis years 15.4 ± 10.5
Etiology of end-stage renal disease n (%)
Diabetic nephropathy 13 (43.3)
Polycystic kidney disease 2 (6.7)
Interstitial nephritis 3 (10.0)
Glomerulonephritis 7 (23.3)
Others 5 (16.7)
Weight kg 51.2 ± 10.1
Previous treatment n (%)
Naïve 21 (70.0)
Relapse 5 (16.6)
Non-viral response 4 (13.3)
Liver cirrhosis n (%) 9 (30.0)
Serum HCV-RNA levels log10IU/mL 5.15 ± 0.95
NS5A inhibitor RAVs n (%) 2 (6.7)
Laboratory data
Hemoglobin g/dL 10.6 ± 1.50
WBC /μL 5484 ± 1760
Neutrophils /μL 3718 ± 1381
Platelets ×104/μL 16.5 ± 6.38
Serum AST IU/L 20.1 ± 13.1
Serum ALT IU/L 16.1 ± 8.21
Serum albumin g/dL 3.40 ± 0.35
BUN mg/dL 51.9 ± 16.5
Serum creatinine mg/dL 9.31 ± 2.39
Serum total bilirubin mg/dL 0.36 ± 0.16
Alpha-fetoprotein ng/mL 2.39 ± 0.98
Data are expressed as median, number (%), or mean ± standard deviation
RAVs resistance-associated variants, BUN blood urea nitrogen, PT-INR international
normalized ratio of prothrombin time
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thermore, 9 patients (30%) had liver cirrhosis and received
previous treatment. The duration of HD was 15.4 ±
10.5 years (range 0.5–35 years), and the cause of end-stage
renal dysfunction was diabetic nephropathy in 13 patients,
polycystic kidney disease in 2 patients, and glomeruloneph-
ritis in 7 patients. The mean HCV level was 5.15 ± 0.95
log10 IU/mL (range, 3.2–6.9 log10 IU/mL). The mean serum
albumin, creatinine, and ALT levels were 3.40 ± 0.35 g/dL,
9.31 ± 2.39 mg/dL, and 16.1 ± 8.21 IU/L, respectively (ranges
2.5–4.0 g/dL, 7.9–15.1 mg/dL, and 4–44 IU/L, respectively).
Furthermore, the RAV NS5A-Y93H was detected in 2
patients (6.9%) while L31M/V was not detected at baseline.Virological response
The patient plasma HCV-RNA levels declined following
administration of the combination therapy (Fig. 2), and
the mean decrease from baseline was 4.4 log10 IU/mL at
week 4. The results of the primary endpoint determin-
ation revealed an SVR24 rate of 83.3% (25/30). The pro-
portions of patients with undetectable HCV-RNA levels
at treatment weeks 4, 8, and 12, and at the treatment
end were 26/30, 30/30, 30/30, and 27/30 (86.7, 100, 100,
and 90.0%), respectively, while at weeks 4, 8, and 12 after
the treatment ended, the proportions were all 25/30
(83.3%). Furthermore, the 3 patients who were followed
up to the discontinuation of the combination therapy,
due to adverse events and laboratory abnormalities,
achieved SVR24.
Virological failure
The demographics of the patients with virological failure
and other baseline clinical characteristics are summa-
rized in Table 2. Virological failure was observed in 4
patients (13.3%), 2 patients exhibiting virological break-
through, one of those at week 16 and the other at week
20 of drug administration, respectively, and viral relapse
occurred in 2 patients, one at week 4 and the other at
week 8 after the treatment ended.
Virological failure had HCV-RNA levels exceeding 5.5
log10 IU/mL, although there were no significant differ-
ences with the virological response and failure group in
the mean viral load. There were no significant differ-
ences with the virological response or failure group in
age, sex, duration of hemodialysis, liver cirrhosis, or pre-
vious treatment.
We also investigated the influence of pretreatment
RAVs of NS5A-L31M/V and Y93H. We discovered that
the patients who showed virological failure did not
exhibit RAVs at baseline, while NS5A-L31M/V and
Y93H were observed at the time of failure.
Pharmacological effects
Following drug administration, a decrease in the mean
ALT level from 16.1 ± 8.21 to 10.2 ± 10.6 IU/IU was ob-
served at the end of the treatment (P = 0.0475). The
baseline and posttreatment serum creatinine levels were
indistinguishable (9.31 ± 2.39 vs. 9.31 ± 3.82 mg/dL,
P = 0.481). The baseline and posttreatment hemoglobin
levels were indistinguishable (10.6 ± 1.50 vs. 10.5 ±
1.82, P = 0.736). There were no significant differences
in the levels of WBC counts, neutrophils, platelets,
serum albumin, BUN, total bilirubin, or α-fetoprotein.
Safety assessment
The observed adverse events are summarized in Table 3.
Adverse events were observed in 10 patients (33.3%)
receiving treatment, and there were no treatment-related
Fig. 2 Change in HCV-RNA levels during treatment with daclatasvir and asunaprevir in complete, relapse, and breakthrough patients. HCV-RNA
levels at baseline, at weeks 0, 2, 4, 8, 12, 16, 20, and 24, and posttreatment at weeks 4, 8, 12, and 24. LLQ lower limit of quantification (IU/mL).
Complete indicates patients with a mean sustained virological response at 24 weeks after the treatment ended
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were reported in 9 patients (30.0%) during the treat-
ment. Although serious adverse events (≥grade 3) were
not reported, there were three adverse events that led to
the discontinuation of the combination therapy. Two pa-
tients, who discontinued therapy, exhibited fatigue at
week 14 and had diarrhea at week 20. Another patient
showed increased ALT levels (grade 2), leading to the
discontinuation of the combination therapy at week 13
due to the physician’s decision (Fig. 3).
Discussion
We evaluated the DCV and ASV combination therapy






Age, years 64.9 ± 8.19 69.5 ± 2.69 0.182
Sex, male (n) [%] 21/25 (80.7) 2/4 (50.0) 0.180†
Duration of hemodialysis (years) 16.1 ± 9.5 15.3 ± 10.4 0.393*
Previous treatment (n) [%]
Naïve 19/25 (76.0) 1/4 (25.0) 0.076†
Relapse and non-viral response 6/25 (24.0) 3/4 (75.0)
Liver cirrhosis (n) [%] 6/25 (24.0) 3/4 (75.0) 0.076†
Serum HCV-RNA levels (log10 IU/mL) 5.06 ± 0.99 5.88 ± 0.28 0.158*
≥5.0 log10 IU/mL (n) [%] 16/25 (64.0) 4/4 (100) 0.280
†
≥5.5 log10 IU/mL (n) [%] 9/25 (36) 4/4 (100) 0.030
†
NS5A inhibitor RAVs (n) [%] 2/25 (8) 0/4 (0) 1.000†
Data are expressed as median, number (%), or mean ± standard deviation
*Mann-Whitney U test, †Fisher’s exact testin patients undergoing HD. In this multiple prospective
study, we demonstrated that the achievement of an
SVR24 in HCV genotype 1b infection in patients on HD
was significantly higher following combination therapy,
and there were a number of virological failures in pa-
tients who had HCV-RNA levels exceeding 5.5 log10 IU/
mL without the RAVs NS5A-L31M/V and Y93H. It is
commonly known that the most important factor related
to the viral response to DAAs is the presence of RAVs
[20]. In a phase III study of a 24-week regimen of DCV
plus ASV, multivariate analysis confirmed that the RAVs,
NS5A-Y93H, and L31M/V were independent of the fac-
tors affecting the response to this combination therapy
(overall response (OR) 17.81; 95% confidence interval
(CI) 7.17–44.25; and OR 26.81; 95% CI 4.61–155.7, re-
spectively). Therefore, the high SVR rate of 83.3%
achieved in this study was assumed to be attributable to
the lower proportion of RAVs, where NS5A-Y93H was
detected in only two cases and L31M/V was not de-
tected at the baseline. The patients with the RAV NS5A-
Y93H fortunately also achieved SVR12.Table 3 Adverse events and laboratory abnormality during the
treatment period
Adverse events Clinical events (n = 10) [n (%)]
Any grade ≥Grade 3
Diarrhea 4 (13.3) 0
Headache 2 (6.7) 0
Bloating 2 (6.7) 0
Fatigue 1 (3.3) 0
ALT increased 1 (3.3) 0
Fig. 3 Individual patient serum ALT levels at weeks 0, 4, 8, 12, 16, 20, and 24 after the administration of daclatasvir and asunaprevir. Only 1 patient
discontinued treatment 12 weeks after commencing therapy due to elevation of serum ALT to 75 IU/l (black arrow). All the other patients continued
through week 24
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number of characteristics of treatment failure in patients
undergoing HD. All of the virological failures occurred
in patients without the RAVs NS5A-Y93H and L31 M/V,
and all patients had HCV-RNA levels exceeding 5.5
log10 IU/mL even though the HCV-RNA quantity was
not correlated with the response to the combination
therapy in patients without renal dysfunction [10]. We
suggested that high viral loads on HD affected the viral
response to direct-acting antiviral agents regardless of
RAVs. According to a recent study, maintenance HD
decreased the HCV-RNA levels in HD patients with
chronic HCV infections [21, 22]. The influence of high
viral loads in patients on HD might be significantly
higher than that on non-uremic patients. Consequently,
hemodialysis, which decreased the HCV-RNA levels,
may affect the viral response of direct antiviral agents.
Furthermore, the SVR rate in the present study was
considerably lower than those in other articles [17, 18].
Another factor that differs from other studies was that
the present study was conducted under the principles of
intent to treat and did not elucidate RAVs NS3 D168.
We also consider that serum concentrations and drug
activity of DCV and ASV combination therapy on
hemodialysis may affect the viral response. Although
DCV and ASV undergo hepatic biotransformation to
more polar but less pharmacologically active compounds
that require intact renal function for their efficient elim-
ination [23], it has been reported that renal impairment
affects the non-renal clearance of many drugs through
mechanisms that appear to include downregulation/inhibition of cytochrome P450 activity by blood uremic
components [23–26]. However, this mechanism is not
clear because there is little data presented to support
this conclusion.
The administration of the combination therapy was
well tolerated in patients with chronic kidney disease
(CKD) undergoing HD, relative to IFN- or ribavirin-
related therapies. It is noteworthy that hemoglobin
declines were not frequent because this regimen was
managed without interruption of ribavirin. The study of
DAAs with ribavirin in stages 4 or 5 CKD including
those in patients on HD demonstrated that declines in
hemoglobin levels were frequent [27]. The absence of
ribavirin could be an advantage in avoiding severe side
effects. However, in the present study, four clinical
events that led to the discontinuation of the combin-
ation therapy must not be ignored. In particular, 1 pa-
tient died of unknown causes during the study period.
This patient had an ischemic heart disease, and he was
found dead at his home. We determined that the sudden
death had been probably due to shock and sudden
failure of the heart's action, and this clinical event
was a nontreatment-related death. It is well known
that the predominant cause of death in patients on
regular dialysis is cardiovascular, and sudden cardiac
death frequently occurs in CKD patients [28]. HCV
infection in patients undergoing HD was also
reported as a cardiovascular risk factor [29, 30]. We
need to consider that HCV patients on dialysis have a
high risk of sudden death due to cardiac disease dur-
ing combination therapy.
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with a relatively small number of patients and a selection
bias. Second, we postulated that the achievement of a
high SVR rate following treatment with the DCV and
ASV combination therapy was likely due to effects of the
RAVs in the patients on HD. However, the evidence to
support the involvement of the RAVs was insufficient,
and further research is warranted to elucidate the other
predictors in combination with RAVs, including NS3
D168. Third, although our results suggested that the
elimination of HCV in patients undergoing HD may
decrease cardiovascular mortality risk, it is not clear
whether or not the DAAs improved the long-term prog-
nosis of these patients. Finally, more detailed in vivo
pharmacokinetic studies of DCV and ASV combination
therapy should be performed and subsequently used to
predict serum concentrations and drug activity.
Conclusions
We demonstrated that DCV and ASV combination DAA
therapy for chronic HCV genotype 1b infection in pa-
tients undergoing HD was significantly effective. Higher
responses to the combination therapy in patients with
low viral loads can be expected. Therefore, hemodialysis,
by decreasing the HCV-RNA levels, could likely affect
the viral response of direct antiviral agents.
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